Leucid Bio

Leucid Bio

Thinking laterally about CAR-T. Develops Autologous and Allogeneic cell and gene Therapies for hard to treat cancers.

Founded 2014

London, United Kingdom 23 employees Series A Total: $11.50M Biotechnology, Health Care

Leucid Bio is a UK-based biotechnology startup founded in 2014, with a focus on developing Autologous and Allogeneic cell and gene Therapies for hard-to-treat cancers. The company's slogan, "Thinking laterally about CAR-T," reflects its innovative approach to progressing novel CAR T therapies that aim to produce a better and more durable response than previous generations. This innovation promises to improve treatment outcomes and save the lives of patients with refractory cancers. In its latest funding round, Leucid Bio raised a significant £11.50M in a Series A investment on 21 October 2021. The investors in this round included prominent names such as Sofinnova Partners, Vulpes Investment Management, Epidarex Capital, British Business Bank, and 2invest. These investments serve as a testament to the confidence that industry leaders have in the potential of Leucid Bio's innovative approach to CAR T therapies. Overall, Leucid Bio's dedication to pushing the boundaries of CAR T therapy and its ability to attract substantial investments from reputable sources such as Sofinnova Partners and Epidarex Capital position it as a noteworthy player in the biotechnology and healthcare industries. This demonstrates the company's potential to make a lasting impact on the treatment of challenging cancers, making it an intriguing prospect for venture capital investors seeking opportunities in the life sciences sector.

Funding Stage	Amount	Investors	Lead Investors	Date
Series A	£11.50M	5	Sofinnova Partners, Epidarex Capital +3	21 Oct 2021

Funding Stage

Amount

Investors

Lead Investors

Date

Series A

£11.50M

Sofinnova Partners, Epidarex Capital +3

21 Oct 2021

FAQ About Leucid Bio

Thinking laterally about CAR-T. Develops Autologous and Allogeneic cell and gene Therapies for hard to treat cancers.

Leucid Bio was founded in 2014.

Leucid Bio is headquartered in London, United Kingdom.

Leucid Bio operates in Biotechnology and Health Care. Its work centres on CAR-T therapies, Autologous cell therapies, Allogeneic cell therapies and Gene therapies.

Leucid Bio has approximately 23 employees.

Leucid Bio has completed 1 funding round, raising a total of $11.50M. The latest funding stage is Series A.

Top alternatives and competitors to Leucid Bio include Tessa Therapeutics Ltd, Zelluna Immunotherapy, Adicet Bio, Inc, Revitope, American Gene Technologies® International Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Leucid Bio and Tessa Therapeutics Ltd are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Leucid Bio

Funding Rounds & Investors (1)

Leucid Bio Alternatives & Competitors

FAQ About Leucid Bio